1-9 of 9
C. L. Beach
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status

Clinical Trials & Observations
Gail J. Roboz, Farhad Ravandi, Andrew H. Wei, Hervé Dombret, Felicitas Thol, Maria Teresa Voso, Andre C. Schuh, Kimmo Porkka, Ignazia La Torre, Barry Skikne, Jianhua Zhong, C. L. Beach, Alberto Risueño, Daniel L. Menezes, Gert Ossenkoppele, Hartmut Döhner
Journal: Blood
Blood (2022) 139 (14): 2145–2155.
https://doi.org/10.1182/blood.2021013404
Published: 2022
Includes: Supplemental data
Journal Articles

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

Clinical Trials & Observations
Hervé Dombret, John F. Seymour, Aleksandra Butrym, Agnieszka Wierzbowska, Dominik Selleslag, Jun Ho Jang, Rajat Kumar, James Cavenagh, Andre C. Schuh, Anna Candoni, Christian Récher, Irwindeep Sandhu, Teresa Bernal del Castillo, Haifa Kathrin Al-Ali, Giovanni Martinelli, Jose Falantes, Richard Noppeney, Richard M. Stone, Mark D. Minden, Heidi McIntyre, Steve Songer, Lela M. Lucy, C. L. Beach, Hartmut Döhner
Journal: Blood
Blood (2015) 126 (3): 291–299.
https://doi.org/10.1182/blood-2015-01-621664
Published: 2015
Includes: Supplemental data
Journal Articles

A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS

John Koreth, MBBS, DPhil, Joseph Pidala, MD, MS, Waleska S. Perez, MPH, H. Joachim Deeg, M.D., Guillermo Garcia-Manero, Luca Malcovati, Mario Cazzola, Sophie Park, Raphael Itzykson, MD, Lionel Ades, Pierre Fenaux, MD, PhD, Martin Jädersten, MD, PhD, Eva Hellstrom-Lindberg, MD, PhD, Robert Peter Gale, MD, PhD, DSc, C. L. Beach, PharmD, Peter L. Greenberg, MD, Martin S. Tallman, MD, John F. DiPersio, MD, PhD, Donald Bunjes, MD, Daniel J. Weisdorf, MD, Corey S. Cutler, MD, MPH, FRCPC
Journal: Blood
Blood (2011) 118 (21): 115.
https://doi.org/10.1182/blood.V118.21.115.115
Published: 2011
Journal Articles

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

Clinical Trials & Observations
Raphael Itzykson, Sylvain Thépot, Bruno Quesnel, Francois Dreyfus, Odile Beyne-Rauzy, Pascal Turlure, Norbert Vey, Christian Recher, Caroline Dartigeas, Laurence Legros, Jacques Delaunay, Célia Salanoubat, Sorin Visanica, Aspasia Stamatoullas, Francoise Isnard, Anne Marfaing-Koka, Stephane de Botton, Youcef Chelghoum, Anne-Laure Taksin, Isabelle Plantier, Shanti Ame, Simone Boehrer, Claude Gardin, C. L. Beach, Lionel Adès, Pierre Fenaux, on behalf of the Groupe Francophone des Myelodysplasies (GFM)
Journal: Blood
Blood (2011) 117 (2): 403–411.
https://doi.org/10.1182/blood-2010-06-289280
Published: 2011
Journal Articles

Comparative Cost-Effectiveness of Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndromes (MDS).

Jeffrey D. Miller, MS, Pierre Fenaux, MD, C. L. Beach, PharmD, Risha Gidwani, DrPH, Zeba M. Khan, RPh, PhD
Journal: Blood
Blood (2009) 114 (22): 1377.
https://doi.org/10.1182/blood.V114.22.1377.1377
Published: 2009
Journal Articles

Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial

John F Seymour, MBBS, PhD, FRACP, Pierre Fenaux, MD, PhD, Lewis B. Silverman, MD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Eva Hellström-Lindberg, MD, PhD, Valeria Santini, MD, Alan F. List, MD, Steven D. Gore, MD, Jay Backstrom, MD, MPH, David McKenzie, MS, C. L. Beach, PharmD
Journal: Blood
Blood (2008) 112 (11): 3629.
https://doi.org/10.1182/blood.V112.11.3629.3629
Published: 2008
Journal Articles

Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA).

Valeria Santini, MD, Pierre Fenaux, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Eva Hellström-Lindberg, MD, PhD, Lewis B. Silverman, MD, Alan List, MD, Steven D. Gore, MD, John F Seymour, MBBS, PhD, FRACP, Jay Backstrom, MD, MPH, David McKenzie, MS, C. L Beach, PharmD
Journal: Blood
Blood (2008) 112 (11): 1653.
https://doi.org/10.1182/blood.V112.11.1653.1653
Published: 2008
Journal Articles

Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR)

Pierre Fenaux, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Eva Hellström-Lindberg, MD, PhD, Valeria Santini, MD, Norbert Gattermann, MD, Guillermo Sanz, MD, PhD, Alan F. List, MD, Steven D. Gore, MD, John F Seymour, MBBS, PhD, FRACP, Jay Backstrom, MD, MPH, Linda Zimmerman, BSN, David McKenzie, MS, C. L. Beach, PharmD, Lewis B. Silverman, MD
Journal: Blood
Blood (2008) 112 (11): 3636.
https://doi.org/10.1182/blood.V112.11.3636.3636
Published: 2008
Journal Articles

The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)

Lewis R. Silverman, MD, Pierre Fenaux, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Valeria Santini, MD, Eva Hellström-Lindberg, MD, PhD, Norbert Gattermann, MD, Guillermo Sanz, MD, PhD, Alan F. List, MD, Steven D. Gore, MD, John F Seymour, MBBS, PhD, FRACP, Jay Backstrom, MD, MPH, David McKenzie, MS, C. L. Beach, PharmD
Journal: Blood
Blood (2008) 112 (11): 227.
https://doi.org/10.1182/blood.V112.11.227.227
Published: 2008